Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells

• Published in: NAR cancer 2022-03, Vol.4 (1), p.zcac007-zcac007
• Main Authors: Florian, Andrea C, Woodley, Chase M, Wang, Jing, Grieb, Brian C, Slota, Macey J, Guerrazzi, Kiana, Hsu, Chih-Yuan, Matlock, Brittany K, Flaherty, David K, Lorey, Shelly L, Fesik, Stephen W, Howard, Gregory C, Liu, Qi, Weissmiller, April M, Tansey, William P
• Format: Article
• Language: English
• Subjects: Cancer gene Regulation, Chromatin and Epigenetics
• ISSN: 2632-8674; 2632-8674
• DOI: 10.1093/narcan/zcac007

Rhabdoid tumors (RT) are rare and deadly pediatric cancers driven by loss of , which encodes the SNF5 component of the SWI/SNF chromatin remodeler. Loss of is associated with a complex set of phenotypic changes including vulnerability to inhibitors of protein synthesis and of the p53 ubiquitin-ligase HDM2. Recently, we discovered small molecule inhibitors of the 'WIN' site of WDR5, which in MLL-rearranged leukemia cells decrease the expression of a set of genes linked to protein synthesis, inducing a translational choke and causing p53-dependent inhibition of proliferation. Here, we characterize how WIN site inhibitors act in RT cells. As in leukemia cells, WIN site inhibition in RT cells causes the comprehensive displacement of WDR5 from chromatin, resulting in a decrease in protein synthesis gene expression. Unlike leukemia cells, however, the growth response of RT cells to WIN site blockade is independent of p53. Exploiting this observation, we demonstrate that WIN site inhibitor synergizes with an HDM2 antagonist to induce p53 and block RT cell proliferation . These data reveal a p53-independent action of WIN site inhibitors and forecast that future strategies to treat RT could be based on dual WDR5/HDM2 inhibition.